Video

Helping Manage the Cost of Cancer with a Patient Lens: Opportunities for Pharmacists

This webcast discusses opportunities for pharmacists to address the cost of cancer care and enable improved access and outcomes for patients. During the webcast, a panel of experts discusses how pharmacists can help minimize costs associated with cancer therapy, including treatment and clinical practice considerations, as well as more direct financial support that can help ensure access to effective therapies for patients. Additional Resource Guide can be found here: https://www.pharmacytimes.com/view/managing-cancer-cost-resource-guide.

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
HPV Immunization, New Data | Image Credit: ©kitsawet | stock.adobe.com
November 20th 2024

Investigators Present New Data About HPV Vaccine, Supporting Its Use

Ashley Gallagher, Associate Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

radiology x-ray lung cancer - Image credit: utah51 | stock.adobe.com
November 18th 2024

CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

FDA approval stamp -- Image credit: Olivier Le Moal | stock.adobe.com
Published: November 15th 2024 | Updated: November 15th 2024

FDA Approves Revumenib for the Treatment of Relapsed or Refractory Acute Leukemia

Gillian McGovern, Assistant Editor
Chronic myeloid leukemia (CML) in accelerated phase with thrombocytosis.
November 15th 2024

FDA Grants New Nilotinib Formulation Approval to Treat Adults With Chronic Myeloid Leukemia

Luke Halpern, Assistant Editor